Dulaglutide (Trulicity) treatment of patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease was associated with lesser estimated glomerular filtration rate (eGFR) decline compared to insulin glargine (glargine) in a clinical trial. This study examined the relationship between dulaglutide or glargine use and eGFR for adults with T2D using real-world data from a U.S. electronic health records from 10/25/2013 to 6/18/2017.
There were 13,869 glargine and 1,222 dulaglutide patients included in the descriptive analyses. Patients with initial eGFR < 60 or < 30 mL/min/1.73m2 were more likely to be treated with glargine than dulaglutide (31.3% v 17.1%, p<0.01; 5.3% v 1.0%, p<0.01, respectively). Multivariable analyses on a matched cohort (N=2,366) found dulaglutide use, compared to glargine use, was associated with a significantly smaller decline in eGFR and a smaller proportion of patients with ≥30% decline in eGFR in the 1-year post-period (Figure 1). With the caveat of limited numbers of patients with severe renal impairment, dulaglutide treatment, compared to glargine, was associated with a smaller decline in renal function in a real-world setting.
K. Boye: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; Eli Lilly and Company. R. Mody: Employee; Self; Eli Lilly and Company. J. Wu: None. M.J. Lage: Consultant; Self; Eli Lilly and Company. Consultant; Spouse/Partner; Eli Lilly and Company. F.T. Botros: Employee; Self; Eli Lilly and Company. B. Woodward: Employee; Self; Eli Lilly and Company.